After the rocky launch of its controversial Alzheimer’s disease drug Aduhelm, Biogen is gearing up for layoffs, STAT News reports. Overall, the staff squeeze could slash expenses by $500 million to $750 million, STAT said.
The PerkinElmer Biotech Bundle is deployed via Amazon CloudFormation and provides the most advanced analytical package for drug discovery available today. Affordable and easy to get started. Learn more.
Unlike some of its Big Pharma peers, Novartis has not been at the forefront of creating new vaccines and treatments against COVID. Now, however, it’s taking its massive R&D budget and targeting not just the current pandemic, but all coronaviruses.
Nurses deserve more than just a “thank you” for all they contribute, but Johnson & Johnson knows that appreciation is a good place to start. Continuing the company’s 120 year commitment to the nursing profession, J&J launched a new digital and print campaign to celebrate nurses and the work they’ve done during the pandemic and beyond.
Over a year after doling out an emergency use authorization for a handful of Philips’ IntelliVue patient monitoring devices, the FDA is doubling down on the regulatory nod.
Selecting the right target to kill off cancer cells while sparing healthy cells has been challenging for companies developing off-the-shelf cell therapies. Now, Senti Bio has promising early data on its CAR-NK therapy, developed from the biotech’s gene circuit platform, in acute myeloid leukemia.
University of Chicago researchers say their novel nanomedicine shrank vascular lesions in mice and stopped the progression of plaque buildup that leads to vascular diseases. The team is working to secure funding for a larger animal study and form a company to test the treatment in people.
Anthem-backed digital health solution Hydrogen Health is rolling out its virtual primary care service for self-insured employers and insurers. Hydrogen Health rolled out its services with Anthem this past summer and is now expanding to multiple Fortune 500 employers and large regional health plans, company executives said, with a plan to be live for an additional 10 million people by the end of 2022.
Less than a month after revealing a plan to spin its consumer health business off as a new publicly traded company, Johnson & Johnson has shed more light on its future by naming new members of its executive committee.
After chalking up half a dozen tuck-in acquisitions throughout its fiscal year 2021—which ended Sept. 30—BD seems poised to outdo itself in 2022. Its first two tuck-in acquisitions of fiscal year 2022 came in rapid succession over the course of just the past week.
Samsung Bioepis represents the marriage of an Asian company and a Western drugmaker with a focus on biosimilars. Now, two other players are reportedly considering a similar merger.
The Nordic life sciences scene is getting an injection of cash. Led by centers such as the Karolinska Institutet and Copenhagen University, the region leads the way in research in the EU by many metrics but has traditionally lacked the vibrant VC scene needed to build large numbers of biotechs. Eir Ventures wants to help change that.
Five years into its lofty goal of funding projects to “cure, prevent or manage all disease within our children’s lifetime,” the Chan Zuckerberg Initiative’s Biohub is getting a major boost.
